Samsung Biologics Co Investor Relations Material

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization (CDMO) based in Incheon, South Korea. The company provides comprehensive services ranging from cell line development to large-scale commercial manufacturing, specializing in biopharmaceutical products such as monoclonal antibodies and vaccines. Samsung Biologics operates several state-of-the-art manufacturing plants, including a new facility under construction that will further increase its production capacity. In addition to manufacturing, the company offers aseptic fill/finish services and laboratory testing to support the biopharmaceuticals it produces. Samsung Biologics is also investing in cutting-edge technologies such as antibody-drug conjugates (ADCs) and mRNA manufacturing to meet growing demand. The company is headquartered in Incheon, South Korea, and its shares are listed on the KRX.